September 2022 in “Journal of The American Academy of Dermatology” Different types of hair loss are linked to COVID-19, with some types possibly increasing risk of getting the virus, while others may be triggered or worsened by the virus.
May 2022 in “F1000Research” During the COVID-19 pandemic, Iraqi women experienced more hair loss and certain skin conditions, while contagious skin infections decreased.
April 2022 in “DOAJ (DOAJ: Directory of Open Access Journals)” Effective hair regrowth after COVID-19 involves psychological support, good nutrition, and hair growth treatments.
January 2022 in “Indian Dermatology Online Journal” Teledermatology effectively managed most skin conditions remotely during the COVID-19 pandemic.
November 2021 in “Research Square (Research Square)” The research found that COVID-19 survivors experienced long-term effects like anemia and hypertension, with age and gender being important factors, but race, income, and education had little to no impact.
August 2021 in “Journal of skin and stem cell” Skin symptoms could help in early COVID-19 diagnosis but more research is needed to confirm their reliability.
June 2021 in “Working paper of public health” Six months after COVID-19, most patients still had autoantibodies.
April 2021 in “Journal of Investigative Dermatology” Female authorship in dermatology publications increased during the COVID-19 pandemic, but women are still underrepresented in senior roles.
January 2021 in “International Journal of Research in Medical Sciences” During the COVID-19 lockdown, there were fewer cases of mild skin issues and more cases of stress-related skin conditions.
December 2020 in “Research Square (Research Square)” The AndroCoV Clinical Scoring is a quick, affordable, and accurate method for diagnosing COVID-19.
October 2022 in “Journal of health sciences and medicine” Middle-aged and elderly men with BPH had higher hospitalization rates for COVID-19.
51 citations,
August 2021 in “Turkish Journal of Medical Sciences” As of December 2021, the most effective COVID-19 treatments were monoclonal antibodies and possibly early-administered convalescent plasma, while several drugs were found ineffective or were still under evaluation.
49 citations,
January 2021 in “Journal of The European Academy of Dermatology and Venereology” Anti-androgens, like finasteride, dutasteride, and spironolactone, may lessen the severity of COVID-19 in men, leading to fewer ICU admissions.
49 citations,
May 2020 in “Frontiers in Public Health” Insulin resistance linked to obesity may increase COVID-19 severity.
42 citations,
July 2021 in “Frontiers in Medicine” Proxalutamide significantly lowered hospital admissions for male COVID-19 patients compared to a placebo.
42 citations,
April 2021 in “Journal of clinical pharmacology” Baricitinib helps treat several diseases, including COVID-19, but has side effects and needs careful monitoring.
40 citations,
October 2020 in “Diabetes and Metabolic Syndrome: Clinical Research and Reviews” Higher androgen levels might make COVID-19 worse, especially in men.
36 citations,
November 2020 in “Journal of The European Academy of Dermatology and Venereology” 5-alpha-reductase inhibitors may reduce COVID-19 symptoms in bald males.
27 citations,
December 2020 in “Experimental Dermatology” Grey hair and baldness may be linked to COVID-19 severity, but more analysis is needed; post-infectious hair loss is related to the severity of the disease and usually recovers within 3-6 months.
26 citations,
September 2020 in “Journal of the European Academy of Dermatology and Venereology” A certain genetic variant in the androgen receptor may predict the severity of COVID-19 in men.
7 citations,
May 2022 in “Skin health and disease” Certain types of rashes in COVID-19 patients may indicate more severe illness and higher risk of death.
6 citations,
May 2021 in “Clinical Chemistry and Laboratory Medicine” Different ACE2 gene versions may affect COVID-19 impact based on age and suggest some hair loss drugs could be potential treatments.
5 citations,
July 2021 in “medRxiv (Cold Spring Harbor Laboratory)” Proxalutamide improved blood markers related to inflammation, immune response, and clotting in COVID-19 patients, potentially reducing hospitalizations.
5 citations,
May 2021 in “International Journal of Infectious Diseases” A man experienced hair loss after getting COVID-19, which improved with treatment and might have been triggered by stress related to the illness.
5 citations,
November 2020 in “medRxiv (Cold Spring Harbor Laboratory)” 5-Alpha-Reductase inhibitors shorten COVID-19 recovery time in men.
4 citations,
March 2022 in “Journal of Infection” Anti-androgen therapy might help protect against COVID-19 infection and reduce death risk.
4 citations,
May 2021 in “Journal of The European Academy of Dermatology and Venereology” Hair loss doesn't affect COVID-19 severity.
2 citations,
September 2022 in “Scholarly journal of otolaryngology” Epipharyngeal Abrasive Therapy helps reduce symptoms in Long COVID patients with chronic epipharyngitis.
2 citations,
September 2021 in “Curēus” Tofacitinib may be safe for COVID-19 patients with alopecia without worsening symptoms, based on two cases.
2 citations,
October 2020 in “Journal of Pharmacy And Bioallied Sciences” Hydroxychloroquine and chloroquine are not recommended for COVID-19 treatment due to insufficient evidence and safety concerns.